Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0QV5T
|
|||
| Former ID |
DAP000771
|
|||
| Drug Name |
Phenprocoumon
|
|||
| Synonyms |
Falithiom; Falithrom; Fencumar; Fenprocoumona; Fenprocumon; Fenprocumone; Liquamar; Marcoumar; Marcumar; Marcuphen; Phenprocoumalol; Phenprocoumarol; Phenprocoumarole; Phenprocoumone; Phenprocoumonum; Phenprocumone; Phenprocumonum; Phenprogramma; Phenylpropylhydroxycumarinum; Fenprocumone [DCIT]; Hexal Brand of Phenprocoumon; Roche Brand of Phenprocoumon; Worwag Brand of Phenprocoumon; U29342; Falithrom (TN); Fenprocoumona [INN-Spanish]; Liquamar (TN); Marcoumar (TN); Marcumar (TN); Phenprocoumone [INN-French]; Phenprocoumonum [INN-Latin]; Ro 1-4849; Phenprocoumon (USAN/INN); Phenprocoumon [USAN:INN:BAN]; 2-hydroxy-3-(1-phenylpropyl)chromen-4-one; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1'-Phenyl-propyl)-4-oxycoumarin [German]; 3-(1-Phenylpropyl)-4-hydroxycoumarin; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenylpropyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Anticoagulants
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H16O3
|
|||
| Canonical SMILES |
CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
|
|||
| InChI |
1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3
|
|||
| InChIKey |
DQDAYGNAKTZFIW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 435-97-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
612021, 7845703, 7980293, 8030662, 10522853, 14848717, 29228465, 42684251, 46506423, 47207126, 47815891, 48416418, 49956264, 56394971, 57309600, 57325861, 76965160, 93302774, 103179879, 103950577, 104253508, 104321863, 106673762, 125823525, 126658557, 127770897, 134338056, 134974499, 135692445, 137126448, 137239431, 142971044, 160964285, 162011455, 162224643, 162652374, 163418248, 164042860, 174529392, 176262013, 178103445, 179326620, 184545898, 186014484, 198993025, 219400682, 223670210, 223705291, 226427577, 227840593
|
|||
| ChEBI ID |
CHEBI:50438
|
|||
| SuperDrug ATC ID |
B01AA04
|
|||
| SuperDrug CAS ID |
cas=000435972
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vitamin K epoxide reductase complex 1 (VKORC1) | Target Info | Inhibitor | [4] |
| KEGG Pathway | Ubiquinone and other terpenoid-quinone biosynthesis | |||
| Pathwhiz Pathway | Vitamin K Metabolism | |||
| Coagulation | ||||
| WikiPathways | PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6839). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011228. | |||
| REF 4 | [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.